Assessment of efficacy and safety of endoscopic lung volume reduction with one-way valves in patients with a very low FEV1

Introduction Endoscopic lung volume reduction (ELVR) with one-way valves produces beneficial outcomes in patients with severe emphysema. Evidence on the efficacy remains unclear in patients with a very low forced expiratory volume in 1 s (FEV1) (≤20% predicted). We aim to compare clinical outcomes of ELVR, in relation to the FEV1 restriction. Methods All data originated from the German Lung Emphysema Registry (Lungenemphysem Register), which is a prospective multicentric observational study for patients with severe emphysema after lung volume reduction. Two groups were formed at baseline: FEV1 ≤20% pred and FEV1 21–45% pred. Pulmonary function tests (FEV1, residual volume, partial pressure of carbon dioxide), training capacity (6-min walk distance (6MWD)), quality of life (modified Medical Research Council dyspnoea scale (mMRC), COPD Assessment Test (CAT), St George's Respiratory Questionnaire (SGRQ)) and adverse events were assessed and compared at baseline and after 3 and 6 months. Results 33 patients with FEV1 ≤20% pred and 265 patients with FEV1 21–45% pred were analysed. After ELVR, an increase in FEV1 was observed in both groups (both p<0.001). The mMRC and CAT scores, and 6MWD improved in both groups (all p<0.05). The SGRQ score improved significantly in the FEV1 21–45% pred group, and by trend in the FEV1 ≤20% pred group. Pneumothorax was the most frequent complication within the first 90 days in both groups (FEV1 ≤20% pred: 7.7% versus FEV1 21–45% pred: 22.1%; p=0.624). No deaths occurred in the FEV1 ≤20% pred group up to 6 months. Conclusion Our study highlights the potential efficacy of one-way valves, even in patients with very low FEV1, as these patients experienced significant improvements in FEV1, 6MWD and quality of life. No death was reported, suggesting a good safety profile, even in these high-risk patients. Tweetable abstract Endoscopic lung volume reduction with valves seems to be a viable treatment option for patients with severe emphysema and a very low FEV1 https://bit.ly/4664uvt

[1]  D. Slebos,et al.  Bronchoscopic Lung Volume Reduction for Emphysema: Review and Update. , 2022, Seminars in respiratory and critical care medicine.

[2]  I. Rudan,et al.  Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis , 2022, The Lancet. Respiratory medicine.

[3]  F. Doellinger,et al.  Impact of Ventilation Modes on Bronchoscopic Chartis Assessment Outcome in Candidates for Endobronchial Valve Treatment , 2021, Respiration.

[4]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[5]  D. Slebos,et al.  Bronchoscopic interventions for severe emphysema: Where are we now? , 2020, Respirology.

[6]  S. Makani,et al.  Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial , 2019, American journal of respiratory and critical care medicine.

[7]  Kevin McCarthy,et al.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.

[8]  J. Wedzicha,et al.  Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. , 2019, The New England journal of medicine.

[9]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[10]  F. Herth,et al.  Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis. , 2019, The Lancet. Respiratory medicine.

[11]  G. Criner,et al.  Endoscopic Lung Volume Reduction: An Expert Panel Recommendation – Update 2019 , 2019, Respiration.

[12]  E. Wouters,et al.  Emphysema: looking beyond alpha-1 antitrypsin deficiency , 2019, Expert review of respiratory medicine.

[13]  A. Sung,et al.  A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE) , 2018, American journal of respiratory and critical care medicine.

[14]  G. Hillerdal,et al.  A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM) , 2017, American journal of respiratory and critical care medicine.

[15]  D. Slebos,et al.  One-Year Follow-Up after Endobronchial Valve Treatment in Patients with Emphysema without Collateral Ventilation Treated in the STELVIO Trial , 2016, Respiration.

[16]  K. Darwiche,et al.  Bronchoscopic Lung Volume Reduction with Endobronchial Valves in Low-FEV1 Patients , 2016, Respiration.

[17]  F. Herth,et al.  Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. , 2016, American journal of respiratory and critical care medicine.

[18]  R. Bals,et al.  Endoscopic Lung Volume Reduction Using Endobronchial Valves in Patients with Severe Emphysema and Very Low FEV1 , 2016, Respiration.

[19]  E. V. van Rikxoort,et al.  Predicting Lung Volume Reduction after Endobronchial Valve Therapy Is Maximized Using a Combination of Diagnostic Tools , 2016, Respiration.

[20]  P. Raffy,et al.  Patterns of Emphysema Heterogeneity , 2015, Respiration.

[21]  D. Hansell,et al.  Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial , 2015, The Lancet.

[22]  R. Kaplan,et al.  Long-term follow-up of high-risk patients in the National Emphysema Treatment Trial. , 2014, The Annals of thoracic surgery.

[23]  M. Noppen,et al.  Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort , 2012, European Respiratory Journal.

[24]  F. Martinez,et al.  The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. , 2011, American journal of respiratory and critical care medicine.

[25]  F. Martinez,et al.  The National Emphysema Treatment Trial (NETT): Part I: Lessons learned about emphysema. , 2011, American journal of respiratory and critical care medicine.

[26]  G. McLennan,et al.  A randomized study of endobronchial valves for advanced emphysema. , 2010, The New England journal of medicine.

[27]  D. O’Donnell,et al.  The major limitation to exercise performance in COPD is dynamic hyperinflation. , 2008, Journal of applied physiology.

[28]  J. Hankinson,et al.  Standardisation of the single-breath determination of carbon monoxide uptake in the lung , 2005, European Respiratory Journal.

[29]  G. Viegi,et al.  Standardisation of the measurement of lung volumes , 2005, European Respiratory Journal.

[30]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[31]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[32]  P. Zipfel,et al.  Conidial Dihydroxynaphthalene Melanin of the Human Pathogenic Fungus Aspergillus fumigatus Interferes with the Host Endocytosis Pathway , 2011, Front. Microbio..

[33]  T. Miyazawa.  [Interventional bronchoscopy]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.

[34]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[35]  G. Criner,et al.  Improvements in lung function, exercise, and quality of life in hypercapnic COPD patients after lung volume reduction surgery. , 1999, Chest.

[36]  H. Thompson,et al.  Prognosis in chronic obstructive pulmonary disease. , 1973, The American review of respiratory disease.